Production and application of Paenibacillus polymyxa levan as an antiviral priming agent against cucumber mosaic virus infection in tobacco plants.

This study investigates the application of levan- produced from Paenibacillus polymyxa SG09-12 as an antiviral agent against cucumber mosaic virus (CMV). A high-purity microbial levan was produced and purified using diafiltration. The chemical composition, structure, and functional groups of the levan were characterised using high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR), Fourier-transform infrared spectroscopy (FT-IR), and X-ray photoelectron spectroscopy (XPS).

Risk assessment and monitoring of tranquilizers in live seafood: Analysis of natural essential oil and 2-phenoxyethanol by GC-MS/MS.

An analytical method for nine tranquilizer compounds, including eight major natural oil components and 2-phenoxyethanol, was developed using gas chromatography tandem mass spectrometry and validated under CODEX and National Institute of Food and Drug Safety Evaluation guidelines. Subsequently, 315 live seafood samples under Korean preference for sashimi (eight species) were monitored with sales distribution channels and place of origin. A total of 76 detection cases in 65 seafood samples contained the target tranquilizer compounds at concentrations ranging from 2.

Impact of the probiotic on loperamide-induced delayed bowel movement in Sprague-Dawley rats.

This study investigated the effects of on alleviating loperamide-induced constipation. To evaluate the efficacy of in Sprague-Dawley (SD) rats, fecal parameters, the intestinal transit rate, and changes in intestinal mucosal cells were measured through histological analysis. Additionally, serotonin levels, water absorption, tight junction-related gene expression, and the cecal short-chain fatty acid (SCFA) content were analyzed.

Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.

Enfortumab vedotin (EV) is used as monotherapy or combined with pembrolizumab in advanced urothelial carcinoma (aUC), but biomarker data associated with EV outcomes are limited. We identified 170 patients in the UNITE study who received EV monotherapy and had molecular biomarker data available. Outcomes for groups with and without a particular biomarker were compared using logistic regression (unadjusted) for the objective response rate (ORR), and a log-rank test and Cox proportional-hazard models (CPHMs) for progression-free survival (PFS) and overall survival (OS) from EV initiation.